Health & Fitness
Health and Fitness
Health and Fitness
Mon, June 27, 2011 MedPro Safety Products Introduces Passive Hypodermic Safety Syringe
LEXINGTON, Ky.--([ BUSINESS WIRE ])--MedPro Safety Products, Inc. (OTCBB:MPSP), a leading developer of transformational technologies that enable safer medication delivery and blood collection, today announced the introduction of its hypodermic safety syringe. The device incorporates a proprietary safety shield that is automatically released during the administration of medicine, covering the needle as it is removed, and thereby enhancing patient and operator safety.
"The passive hypodermic safety syringe is the latest offering in our efforts to expand our patented passive safety technology across a broad range of products"
The passive (automatic) hypodermic safety syringe provides unique features and benefits. The passive safety mechanism is integrated into the syringe and is activated through the normal process of medication delivery. The shield is automatically deployed over the contaminated needle, reducing the chances of a needlestick injury. It prevents recapping, removal and reuse of the syringe with the engagements of its auto-disable feature and reduces the chance of blood or drug splatter. The device is easy to use and provides an unobstructed view of the patient during an injection.
aThe passive hypodermic safety syringe is the latest offering in our efforts to expand our patented passive safety technology across a broad range of products,a said Craig Turner, CEO of MedPro Safety Products. aThis development demonstrates the strength of our research and development effort. We are in various stages of discussions with several potential partners to explore the commercialization of the hypodermic safety syringe and we will be featuring this new product at the Annual APIC Conference in Baltimore running from June 27 through June 29.a
About MedPro Safety Products, Inc.
Headquartered in Lexington, Kentucky, MedPro Safety Products, Inc. is a leading developer of safer medication delivery and blood collection systems. The Company licenses, develops and manufactures transformational technologies marketed through its global medical device partners. MedProa™s portfolio addresses multiple product categories within the medical delivery (injection and infusion) and blood collection (blood collection sets and blood tube holders) markets. These products incorporate needlestick prevention features considered to be the most passive now available on the market as they require little or no clinician training compared to competitive products. The total global market opportunity currently addressed by the Companya™s products is estimated to be in excess of $6 billion. For additional information, please refer to the aInvestor Relationsa™ link on MedProa™s website ([ http://www.medprosafety.com ]).
Safe Harbor Statement
This release includes forward-looking statements based upon current expectations of the management of MedPro Safety Products, Inc. that involve risks and uncertainties, such as plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including our ability to identify and acquire medical safety device safety technologies with product development potential; our ability to successfully develop and bring products to market, including obtaining regulatory approvals; our ability to successfully increase sales of our products; our ability to obtain additional financing on satisfactory terms; our ability to attract and retain qualified employees; and governmental regulation associated with the medical safety products industry. Words such as "anticipate," "estimate," "plan," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," and similar expressions are used to identify forward-looking statements. We refer you to the more detailed discussion of risks and uncertainties under "Risk Factors" in our Annual Report on Form 10-K and our other reports on file with the Securities and Exchange Commission.
